Last Updated: Jul 06 2011 - Silobreaker


Fact Sheet for MAP Pharmaceuticals Inc

Name: MAP Pharmaceuticals Inc
Nationality: United States
Contact Address: 2400 Bayshore Parkway, Suite 200 Mountain View, CA 94043 United States Tel: +1 650-386-3100 Fax: +1 650-386-3101
WebAddress: http://www.mappharma.com/
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First reported May 22 2013 - Updated May 22 2013 - 1 reports

MAP Pharmaceuticals Crosses Above its...

MAP Pharmaceuticals (NASDAQ:MAPP) crossed over its 10-day moving average of $13.27 on a volume of 808K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term. MAP ... [Published Financial News Network online - May 22 2013]
First reported May 13 2013 - Updated May 13 2013 - 1 reports

Allergan reports lower Q1 net income, provides guidance for Q2 and 2013

Allergan, Inc., a healthcare company, has reported that net income attributable to the company for the first quarter ended March 31, 2013 was $12.5 million, or $0.04 per diluted share, compared to $229.8 million, or $0.74 per diluted share, for the same ... [Published Individual.com - May 13 2013]
First reported May 06 2013 - Updated May 06 2013 - 1 reports

Allergan Releases 1Q 2013 Operating Results

Allergan, Inc. has announced operating results for the quarter ended March 31. In a release on May 1, the Company also announced that its Board of Directors has declared a first quarter dividend of $0.05 per share, payable on June 13, to stockholders ... [Published Individual.com - May 06 2013]
First reported May 01 2013 - Updated May 02 2013 - 2 reports

Allergan shares slide on eye drug delay

Allergan's stock has taken a hit - despite posting better-than-expected first-quarter results - after the group revealed it will delay Phase III testing of its investigational eye drug on weak mid-stage data.The Irvine, California-based company had reportedly ... [Published Pharma Times - May 02 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Allergan Q1 Results Top Estimates; Cuts 2013 EPS Outlook

Multi-specialty health care company Allergan, Inc. (AGN: Quote) reported Wednesday a profit for the first quarter that increased from last year, boosted by revenue growth amid 8.4 percent product sales increase.Both adjusted earnings per share from continuing ... [Published RTTNews.com - May 01 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports
Allergan Inc
Allergan Inc

Allergan Q1 Profit Slumps - Quick Facts

Multi-specialty health care company Allergan Inc. (AGN: Quote) reported a sharp plunge in first-quarter GAAP net earnings attributable to the company to $12.5 million, or $0.04 per share, from $229.8 million, or $0.74 per share a year before. On a continuing ... [Published RTTNews.com - May 01 2013]
First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports
MAP Pharmaceuticals Inc
MAP Pharmaceuticals Inc

Stock Investors Sell Off Shares of MAP...

One of today's stocks on the move is MAP Pharmaceuticals (NASDAQ:MAPP), down 3.6% to $14.81. The S&P is trading lower by 1.9% to 1,401 and the Dow is trading 2.0% lower to 12,985. MAP Pharmaceuticals Inc. is a biopharmaceutical company. The Company develops ... [Published Financial News Network online - Apr 29 2013]
First reported Apr 16 2013 - Updated Apr 17 2013 - 4 reports

Manufacturing problems keep Allergan from drug approval

FDA has issues with how inhaler canisters are filledShareToolsManufacturing problems are again standing in the way of a drug launch, with the FDA holding off approval of Allergan's ($AGN) new migraine treatment until problems at an inhaler plant are sorted ... [Published FierceBiotech - Apr 16 2013]
First reported Mar 01 2013 - Updated Mar 01 2013 - 1 reports

8-K - MAP Pharmaceuticals, Inc. (0001401923) (Filer)

Filed: 2013-03-01 AccNo: 0001193125-13-088005 Size: 134 KBItem 2.01: Completion of Acquisition or Disposition of AssetsItem 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.02: Unregistered ... [Published SEC Filings - Mar 01 2013]
First reported Jan 24 2013 - Updated Jan 24 2013 - 2 reports

Allergan to buy MAP Pharma for $958 million

Allergan, Inc. and MAP Pharmaceuticals, Inc. have entered into a definitive merger agreement whereby Allergan will acquire 100 per cent of the shares of MAP Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is a biopharmaceutical company ... [Published PharmaBiz - Jan 24 2013]
First reported Jan 23 2013 - Updated Jan 24 2013 - 3 reports

Allergan's Acquisition Of MAP Pharmaceuticals Is A Bargain

ByPropThink: By Dee Kotak, M.D. Our recent analysis of MAP Pharmaceuticals ( MAPP ) highlighted the market potential of the orally inhaled Levadex for the treatment of acute migraine and the high likelihood of success on the upcoming PDUFA date. ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Jan 23 2013]
First reported Jan 23 2013 - Updated Jan 23 2013 - 1 reports

Pharmacy News

Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc. IRVINE, Calif. & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today jointly announced that they have entered into a definitive merger agreement ... [Published Rx Times Pharmacy Magazine - Jan 23 2013]
In Focus
Network
Network

Blogs

sort by: Date | Relevance
Pharmacy News [Published Rx Times Pharmacy Magazine - Jan 23 2013]
Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc. IRVINE, Calif. & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today jointly announced that they have entered into a definitive merger agreement ...
Allergan to Buy MAP Pharmaceuticals for $958 Mi... [Published DealBook - Jan 23 2013]
The purchase price, a 60 percent premium over MAP's closing price on Tuesday, suggests that Allergan has great faith that MAP's new migraine treatment will win regulatory approval from the Food and Drug Administration. ...
Clorox Cleans Up and 3 Stocks Hitting 52-week H... [Published Wall St. Cheat Sheet - Feb 25 2013]
The Clorox Company ( NYSE:CLX ): Closing price $83.13 Procter & Gamble might well be more popular in the household products space, but Clorox is seen by some analysts as the  superior investment , as the firm should see greater growth this year, is less expensive compared ...
Pharmalot… Pharmalittle… Good Morning [Published Pharmalot - Jan 23 2013]
Rise and shine, another chilly day is on the way. A shiny frost has enveloped the Pharmalot corporate campus this morning as we struggle to fire the furnace and deposit the short people at various houses of learning. Another way to keep warm, of course, ...
Google’s Q4 Results Highlight Health and 4 Stoc... [Published Wall St. Cheat Sheet - Jan 23 2013]
Intuitive Surgical, Inc.  ( NASDAQ:ISRG ):  Current price $574.41 Following the company’s fourth quarter results, Lazard Capital raised their price target for Intuitive Surgical, Inc. and the firm keeps a Buy rating on the stock. Markets are ...
1 2

Audio/Video

sort by: Date | Relevance
The Top Ten Stocks for Wednesday, January 23 [Published Bloomberg - YouTube - Jan 23 2013]
1

Press Releases

sort by: Date | Relevance
Allergan, Inc. to Acquire MAP Pharmaceuticals, ... [Published Business Wire Health News - Jan 23 2013]
Allergan, Inc. to Acquire MAP Pharmaceuticals, ... [Published EON Health & Medicine - Jan 23 2013]
MAP Pharmaceuticals, Inc. Shareholder Alert: Be... [Published Financial Services - Jan 23 2013]
MAP Pharmaceuticals to Present at the 31st Annu... [Published PR Newswire: General Business - Jan 02 2013]
Law Office of Brodsky & Smith, LLC Announces In... [Published Financial Services - Jan 24 2013]
1 2 3 4 5 6 7 8 9 10 ...
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.